Cassava Sciences: REFOCUS Unlikely To Save Simufilam, Careful Development Needed
Cassava Sciences' Alzheimer's drug trials disappointed, leading to early study discontinuations. Check out why I rate SAVA ...
Cassava Sciences: Probably The End Of The Saga
Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...
GlobalData on MSN6d
Cassava Sciences stock plummets after Phase III Alzheimer’s fail
Following the ReThink study failure, Cassava Sciences is discontinuing the Phase III ReFocus trial and open-label study.
thedeepdive6d
Cassava Sciences Stock Plummets Amid Trial Failure and Shkreli’s Takedown
Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...
Fintel on MSN6d
HC Wainwright & Co. Downgrades Cassava Sciences (SAVA)
Fintel reports that on November 26, 2024, HC Wainwright & Co. downgraded their outlook for Cassava Sciences (NasdaqCM:SAVA) ...
STAT6d
Cassava Sciences and its Alzheimer’s drug are done. The damage lingers
The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...
Shareholder Rights Advocates at Levi & Korsinsky Investigate Cassava Sciences, Inc. (SAVA) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / December 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...
Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results
Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...
A Controversial Alzheimer’s Drug Has Gone Down in Flames
Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...
Cassava Sciences, Inc. Being Investigated on Behalf of Cassava Sciences, Inc. Investors. Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...
Yahoo6d
Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops
Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing. Roche's Proposed ...
FY2024 EPS Estimate for Cassava Sciences Reduced by Analyst
Research analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Cassava Sciences in a research report issued on Tuesday, November 26th. HC Wainwright analyst V. Bernardino ...